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Abstract 
Colon and Colorectal cancer are a diagnosis of particular concern for older Canadians. They are the second cancer in terms of rate 
of incidence and mortality among Canadians after lung cancer. Treatment of colon and colorectal cancer requires a complex 
decision-making process of treatment. These treatments may involve surgery and either pre- or post-operative radiation or 
chemotherapy, which can have a great impact on the quality of life of patients due to the rigorous requirements of treatment and 
the inconvenient side effects. This paper is the first developmental step of an agent-based simulation platform aiming at simulating 
colon and colorectal cancer patient care trajectories in a hospital. In this study, we describe a virtual patient agent, which includes 
a cancer evolution model, capable of replicating cancer behavior in response to treatment. Simulation results show promising 
interpolation results with respect to chemotherapy dosage and radiotherapy dosage. However, the model ability to interpolate 
different administration protocols is still limited, and therefore require calibration for each protocol. 
© 2016 The Authors. Published by Elsevier B.V. 
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1. Introduction and Motivation 
Almost half Canadians (41 % women and 46 % men) will develop cancer during their lifetime and 88 % of them are older 
than fifty [1]. Lung, breast, colon, colorectal and prostate cancers represent more than half of all new cancer cases (52 %). 
Breast cancer is the leading type of cancer among women, while colon and colorectal cancer are the third most common 
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cancer among men and women. Cancer is the leading cause of death in Canada and in the world [2] with 29.8 % of the 
population affected, compared to 26.6 % for cardiovascular diseases. Furthermore, in 2000, cancer was the fourth most 
expensive disease in Canada with $ 17.4 billions spent. Colon and Colorectal cancer are considered the second leading cause 
of cancer death among men and the third among women. 
Cancer treatment is characterized by the convergence of many services including ambulatory, hospitals, clinical, 
nutritional, psychological, and sports medicine, which coordination and integration condition treatment success and patient 
quality of life. In order to reduce the impact of this disease and increase the cure rate and the patient quality of life, it is 
necessary to develop and evaluate new therapeutic and organizational approaches.  
The general objective requires the modeling and simulation of complex behaviors, decision-making processes and 
interactions between hospital staff and patients, therefore to create and validate the patient agent model, which includes a 
physiological model of how the cancer evolves in time in response to specific treatments. This study deals with this goal and 
is the first methodological step toward creating a simulation platform of care trajectories of colon and colorectal cancer 
patients. This simulation platform aims at simulating many elements of the hospital environment, from care resources to 
patient physiology and psychology profiles, in order to evaluate the many impacts of organizational changes of care 
trajectories. Also, the simulation model will include: the physical health of the patient; the cognitive state of the patient; the 
psychosocial state of the patients; the hospital resources, staff and physicians. In other words, factors such as socio-
demographic and environmental characteristics, as well as the characteristics of the organizational and decision-making 
systems, will be used to simulate patient care trajectories, from their diagnosis to the end of the treatment. This simulation 
environment will support the simultaneous optimization of resources utilization and care quality by assessing the 
performance of multiple patient care trajectories in a virtual hospital based on reengineered organizational and medical 
procedure of the Montreal General Jewish Hospital. In this study, agent-based simulation is used as the main modeling 
paradigm, because it allows the researcher to model the actors (e.g., patient, physician, nurse, and support staff) involved in 
the care trajectory and their interactions in a natural and anthropomorphic manner. 
In order to achieve this specific objective, several challenges must be addressed. The first methodological challenge 
concerns the development of the cancer evolution model. Cancer evolution in time, and particularly during treatment, is an 
important part of this study. It is the central model of proposed the simulation environment, because (a) it has an impact on 
resource utilization and decision processes, and (b) it is impacted by all medical and organizational decisions and resource 
availability, as well as the patient condition, environment and support. Therefore, having a representative cancer model is 
essential to this project.  
This paper focuses specifically on the first developmental step of this simulation model, which concerns the development 
of an agent-based model of colon and colorectal cancer patients. This includes a general conceptual model and a cancer 
evolution model under different kinds of treatment. The next section presents a state-of-the-art of simulation application to 
the medical domain. 
2. State of art 
Simulation is a proven methodological tool to study the intrinsic complexity of dynamic systems, which behavior emerges 
from the interactions of a multitude of elements. Artificial, biological, as well as psychosocial systems involved in healthcare-
related issues are complex in nature. Most simulation technics have been used to study and analyze these systems, including 
Monte Carlo simulation, Discrete-Event Simulation, System Dynamics and Agent-Based Simulation. In general, computer 
simulations are used to better understand the impacts of specific decisions, policies, or systems configurations through the 
use of virtual computer emulation of real systems. Computer simulations can also be used in educational settings in order to 
develop specific skills, in which students control part of the computer variables through user interfaces. This section presents 
different simulation applications in the medical domain as a tool to improve care quality and services. 
2.1. Simulation technics and applications in the medical domain 
As briefly mentioned, several simulation technics have being used in the medical domain. Each technic has its pros and 
cons and are appropriate for specific contexts. First, Monte Carlo simulation uses, repeatedly, random sets of numbers from 
known probability distribution of different sources of uncertainty (i.e., the environment), in order to compute the results of 
a mathematical model or algorithm (i.e., the system's model), from which we can infer the general behavior or performance 
of that system. It is used in practice when the behavior of the system cannot be easily calculated analytically. Discrete-Event 
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Simulation aims at creating simulation models in the form of queuing-type systems, in which time moves forward either by 
equal time increments or from one event to the next. In such models, events and flows between components occur according 
to probability distributions, which defines processing and transit times, and priority rules. Next, System Dynamics aims at 
modeling complex systems in order to analyze their general behavior. System Dynamics uses a top-down modeling approach 
based on stocks, flows, feedback loops and time delays. Such models only simulate the high-level interactions between the 
general components of a system by simulating the ripple effect of changes associated with their mutual dependencies. System 
Dynamics does not model the elementary interactions between the individual elements of the system, which is what Agent-
Based Simulation aims to model and simulate. Agent-Based Simulation is an emerging simulation tool (Macal & North, 
2006), which takes a bottom-up approach to model the individual behaviors and interactions of a system's elements, referred 
to as agents. Hence, instead of modeling the relationships between the components of a system, Agent-Based Simulation 
captures how the individual elements of a system behave with respect to their own local environment and state, and how 
they interact, communicate, make collective decisions, or influence each other. The Agent-Based Simulation modeling 
paradigm generally uses theoretical or empirical models to capture individual behaviors.  
In the medical domain, [3] identifies 200 papers, in which simulation is used. More than 70% of these applications used 
Monte Carlo simulation, while 20% used Discrete-Event Simulation, less than 9% used System Dynamics, and finally only 
1% used Agent-Based Simulation. Furthermore, the aims and scopes of these studies are extremely varied. [4] presents an 
extensive review of these applications. The authors classified these applications into two categories: the management of 
patient flow and the allocation of resources. More recently, [5] adds additional categories to the previous classification, 
including infection studies, communicable diseases, costs, economic evaluation and screening. Along the same line, [6] 
mentions the following domains of healthcare simulation: hospital systems, hospital departments, ambulatory care, health 
care systems planning, health care models, and medical decision making. Similarly, [3] mention that such models are used 
to study different types of issues including health risk, cost effectiveness of patient care strategies, transmission of diseases, 
health service organization and public health policy evaluation. For instance, [7] use ABS to reorganize hospital emergency 
departments. Recently, several simulation techniques have been used in conjunction to capture different dimensions. For 
instance, [8] use both DES and ABS to model a healthcare system, in which patients choose their hospital based on a linear 
additive service function of three factors (i.e., hospital reputation, travel distance, waiting time). Finally, [9] propose one of 
the first systematic studies aiming at comparing SD and ABS based on a simple mathematical model of interactions between 
a tumor and immune cells. The authors concluded that both modeling paradigms are not always equivalent. The next sub-
sections first introduce the general concept of agent. Then, a state-of-the-art in agent-based simulation in the medical domain 
is presented.  
2.2. Agent-based simulation in the medical domain 
Research in agent-based simulation is prolific. It is known under different labels, including multi-agent simulation, 
individual-based models and agent-based models. These simulation tools are part of a more generic technology known as 
multi-agent systems, which domain of applications is much larger than simulation. In the literature, the concept of agent is 
generally defined as ([10]) "…a computer system situated in an environment, which is a way autonomous and flexible to 
achieve the objectives for which it was designed." 
Healthcare operations management is a domain that is well suited to agent-based simulation because it involves many 
interacting people with their own decision-processes. With agent-based modeling, it is possible to explicitly model these 
individuals and their interactions. However, although agent-based simulation is growing in the medical domain, applications 
to the real world are still rare ([11], [12]).  
In most organizational simulations in the medical field, agents, whether patients, doctors or nurses are of reactive type 
and their behavior are very specific to the purpose of the simulation. For instance, [13-14] use simulation in order to analyze 
the performance of an emergency department in different configurations. In these studies, agents are used to model resources 
that move through the hospital with predefined process time. Modeling in these studies deals mainly with the different types 
of treatment associated with their time and resources requirements, which then become predefined in the simulation. Only 
patients arrival time and resources availabilities change dynamically [15]. In these models, the agents travelling times within 
the hospital is predefined. However, it can also be dynamically computed in the simulation as in [16], which models the 
evacuation of an hospital undergoing a fire, or in [17] that use simulation to study different transport configurations for clean 
and dirty equipment in the hospital.  
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In [8], the patient agent has a more advanced behavior because it can chose the hospital for treatment according to various 
criteria such as quality of care and waiting times. Although, its choice is the result of a simple algorithm, this represents an 
agent which behavior aims at maximizing a preference according to the state of its environment.  
In [18], the authors goes further and model the interaction between the type II diabetic patient and the doctor in order to 
study the impact of such negotiations on the effectiveness and cost of treatment. In [19], the authors model extensively a 
diabetic patient, taking into account the evolution of his illness according to choice of treatment. This is the aim of this paper, 
with a focus on colon and colorectal cancer patient. 
In the next section we present our general conceptual model in order to guide the development the simulation platform. 
3. Patient agent models 
The patient is the central actor of the healthcare system or real system. It interacts with many resources, including 
physicians, nurses and equipment. Its dynamic condition is the main driver of resource utilization, and its reaction to 
treatment defines the system quality level. In order to design such an agent, different models are proposed to describe its 
place in the overall system, and its complex behavior. The general conceptual model proposed in this study defines the main 
interactions between the patient and its environment (Fig. 1). It is composed of four dimensions and includes different aspects 
of the patient, its environment, and the healthcare system. These dimensions are related to physiology of the patient, the 
psychosocial state and support of the patient, the decision processes and the resources use to treat the patient. The links 
between the different aspects identified within these four dimensions represent their mutual dependencies. The central 
(colored) part represents the patient agent. The other parts represent the hospital staff involved in the treatment selection, as 
well as patient support (e.g., family members, nurses).  
Psychosocial dimension: The psychological dimension includes an emotional model of the patient agent and its social 
influences, especially in the form of support from family members and nurses. This model describes a response to specific 
situations. This model will eventually contribute to measuring the patient quality of life during treatment. 
Fig. 1. General conceptual model 
Physiological dimension: this dimension includes both the patient’s health model (its general physical and health 
condition) and its cancer evolution model. Both are affected by treatment in different manners, while influencing each other. 
In practice, this dimension includes on the one hand, the absolute physiological state of the patient and cancer, and, on the 
other hand, the perception of this state obtained from observations (e.g., analysis, scans, and biopsies). While the first 
information is not necessarily known, the second can be out-dated, and more or less accurate. The variable describing the 
cancer evolution model in particular is described in the next section. Finally, in this model, the patient health model is 
influenced by his or her emotional model. 
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Decision dimension: This dimension includes both the patient’s and the physician’s decision models. It represents the 
main actors’ decision-making processes and preferences that contribute to treatment selection and treatment implementation. 
It is the part of the conceptual model that directly contributes to the decision and implementation of patient care trajectories. 
Here, the patient decision model is influenced by its health and emotional models, while the physician decision model is 
influenced by the patient cancer and health models. The patient decision model also contributes to plan each individual 
treatment according to the system resource availabilities. 
System dimension: The system dimension represents the virtual hospital resources and processes. When a physician 
requests a type of treatment, it must be plan according to the hospital priority, the workload of the resources required for this 
kind of treatment, as well as the preferences of the patient.  
The different sub-models of these dimensions influences each other in order to emulate the general relationships between 
the patient, his/her cancer, the medical staff, and the patient's support. The relationship between the patient and the hospital 
processes and resources are addressed through the dynamic specification of the treatment program into the care trajectories, 
which defines how the patient interacts with the different resources for his/her treatment and tests/scans. The next section 
focuses on the cancer evolution model and the link between cancer evolution and the physician decision model. 
4. Cancer evolution model 
Modeling the evolution of cancer is an important step for the simulation of care trajectories. In order to do this, the cancer 
will be modeled into two parts, the main tumor and metastases. Metastases are meant as a general term referring to every 
cancerous cell found in the patient’s body that are not part of the main tumor. This may be an isolated cell traveling in the 
patient's body or a small tumor hooked somewhere else than the main tumor. The main tumor size and the number of 
metastases are two important information as they influence the decision about the treatment [20]. Both will be simulated 
from their appearance (size 1 cell for the tumor and no metastasis) to the end of the treatment. It is useful to model the 
evolution of the cancer before the diagnosis so that out of treatment evolution parameters can be validated and the distribution 
of metastasis density can be known. The evolution of the tumor model that will be described later has four parts: a free 
evolution and the three evolutions under each of the three treatments, which are radiation therapy, surgery and chemotherapy 
developments. 
For the metastases evolution model, there are only two parts: as for the tumor model, a free evolution and an evolution 
under chemotherapy. There is no special evolution under radiation therapy because it has no effect on metastasis other than 
to reduce the emission of cancerous cells by the main tumor.  
4.1. Tumor free growth 
There is a lot of mathematical models of tumor growth based essentially on population-based models [21]. The original 
population-based model was developed by Maltus at the end of the 18e century, using equation (1): 
ܸܽݎ݅ܽݐ݅݋݊ ൌ ܰݑܾ݉݁ݎ݋݂ܾ݅ݎݐ݄ െ ܰݑܾ݉݁ݎ݋݂݀݁ܽݐ݄             (1) 
Where Xp(t) is the tumor size over time given in numbers of cells. One of the most common formulas used for g(x) is an 
empirical law (see equation 2) described by Gompertz in 1825 [21], which describes the evolution of the main tumor from 
the appearance of the first cancerous cell to a larger tumor. 
݃ሺݔሻ ൌ ܽ כ ݔ כ ቀ௕௫ቁ        (2) 
with a being the rate of tumor growth (it is related to doubling time (DT) of the tumor); b is a constant equals ͳͲଵଶ and 
represents a maximum diameter of 12.4 cm (this value is used in most studies on solid tumours). Other tumour growth 
models exist, such as logistic and exponential models. The Gyllenberg-Webb model divides the evolution of the tumor in 
different phases depending on its size in order to describe its evolution more precisely [22].  
In the simulation, the Gompertzian formula for the tumor free evolution was used. In order to determine a, we used [23], 
which characterizes the tumor growth of 27 patients suffering from colorectal cancer. Using this empirical study, we 
computed a Weibull distribution law of the doubling time, from which we randomly generated a doubling time DT. Assuming 
g(Xp(t)) Xp’(t) 
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that this doubling time is a constant over the tumor growth, this allows us to calculate the time it takes for the tumor to be a 
given percentage P of the maximum size b using equation (3). 
ܶݑ݉݋ݑݎܵ݅ݖ݁ሺݐሻ ൌ ݁ౢ౤ሺమሻವ೅ כ௧      (3) 
Once the T is known, a is calculated using the Gompertz curve function, therefore, the link between the doubling time 
and a can be calculated using equation (4). 
ܽ ൌ െ ୪୬ቀି
ౢ౤ሺುሻ
ౢ౤ሺ್ሻቁכ
ౢ౤ሺమሻ
ವ೅
୪୬ሺ௉כ௕ሻ          (4) 
4.2. Tumor growth after radiation therapy  
First, only external radiation therapy is modeled. Its impact on the size of the tumor is calculated one session at a time. 
Consequently, the remaining number of cells is the number of cells before treatment multiplied by the percentage of surviving 
cells S represented by equation (5) from [24].  
ܵ ൌ ݁ି஺൫ఈכௗାఉכௗమ൯ା஻                   (5) 
with Į and ȕ being constants for colon and colorectal cancer, respectively 0.339 and 0.067, as empirically estimated by 
[25]; d is the dose used during the session; and A and B are two parameters associated with the patient, corresponding to the 
effect of a variety of factors. They follow a normal distribution determined using [25]. This model is based on two 
assumptions. First, each cell that cannot further divide itself after the radiation therapy session, is considered dead. Second, 
the tumor keeps growing freely between sessions.  
4.3. Tumor growth during chemotherapy 
The action of chemotherapy is determined using a model developed and tested with two types of chemotherapy drug (i.e., 
Fluorouracil and Capecitabine) on colon and colorectal cancer [26]. Based on this study, the function g(x) in equation (1) is 
described by equations (6) and (7): 
                           ݃ሺݔሻ ൌ  ൫ܽ௖ െ ܧሺݐሻ൯ כ ݔ                                                                          (6)  
ܧሺݐሻ ൌ ܧͲ כ σ ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊ሺݐǡ ௜ܶሻ௜          (7) 
With ac being the exponential growth factor of the tumor. It is determined according to the parameters of the Gompertzien 
growth and the tumor size at the beginning of chemotherapy. Concentration (t, Ti) represents the function of drug 
concentration injected at time T during session i, in the patient’s body over time. E0 is the effect of the drug on the decrease 
of the tumor [21]. E0 depends on the patient and on the type of treatment. We model three types of drug administration: 
Oral, injection with syringe and long injection like Portacaths [27] and Piccline [28]. The function of concentration of drug 
in the patient’s body over time is different for these three types of administration (see equations 8, 9 and 10), based on [26] 
and [21].  
For injection with syringe and oral administration:
ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊ሺݐǡ ௜ܶሻ ൌ ܦ݋ݏ݁ כ ൬ଵଶ ൅
ଵ
ଶ כ ݐ݄ܽ݊൫݇ሺݐ െ ௜ܶሻ൯൰ כ ݁൫஺௕௦௢௥௣௧௜௢௡כሺ்೔ି௧ሻ൯    (8) 
with Absorption being the speed of drug elimination from the patient’s body; k is the speed of drug assimilation; and 
Dose is the dose injected during the session. The only different between injection with syringe and oral administration is k, 
which is bigger for injection. 
For long injection: 
Concerning long injection, the only new parameter is duration, which is the length of time of the injection, as shown in 
equation (9). 
ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊ሺݐǡ ௜ܶሻ ൌ ܦ݋ݏ݁ כ ൬ଵଶ ൅
ଵ
ଶ כ ݐ݄ܽ݊൫݇ሺݐ െ ௜ܶሻ൯൰ כ
݁൬
భ
మା
భ
మכ௧௔௡௛൫ଵ଴ሺ௧ି்೔ିௗ௨௥௔௧௜௢௡ሻ൯൰כ൫஺௕௦௢௥௣௧௜௢௡כሺ்೔ି௧ାௗ௨௥௔௧௜௢௡ሻ൯                                                                                           (9) 
Finally, the function of the tumor’s size during chemotherapy is:
ܺ௣௖൫ܵ ೎்ǡ ݐ൯ ൌ ܵ ೎்݁׬ ൫௔೎ିாሺ௦ሻ൯
೟
೅೎ ௗ௦ݓ݅ݐ݄ݐ ൐ ௖ܶ     (10) 
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with ܵ ೎்  is the tumour’s size before the beginning of chemotherapy. This value is also used in the metastatic evolution 
model. 
4.4. Tumor growth after surgery  
The effect of surgery on the size of the tumor is simpler than the other two treatments described above. Indeed, depending 
on the cancer (colon or rectum) and the type of surgery, the effect of the surgery can be described as a probability of having 
cancerous cells from the main tumor remaining in the body. The next section presents an illustrative example of a cancer 
patient treated with two treatments. 
4.5. Metastases growth 
For the development of metastases, we use a model developed by Iwata ([29]). In this model, the growth of main tumor 
and the metastases are described by a set of mathematical equations. The tumor growth is modeled by ܺ௣ሺݐሻ, which can 
either be the Gompertzian function (2) or the exponential function (3). Next metastases growth, produced by the main tumor 
and other metastases, is described by equation (11).  
ߚሺݔሻ ൌ ݉ כ ݔఈଶ         (11) 
with m being the coefficient of colonization, and Į2 being the fractal dimension of blood vessels infiltrating the tumor.  
Considering that all tumors evolve similarly is not entirely correct. Indeed, although they all originate from the main 
tumor (i.e., their nature is similar), their spread and evolution depend on their location. However, accurately modeled 
movement of each tumor cell in the body is impossible. The Iwata model and its assumptions are considered valid and used 
in the majority of evolution models of metastases. Iwata’s model is defined by the system of equation (12): 
ە
۔
ۓ డఘ
ሺ௫ǡ௧ሻ
డ௧ ൅
డ௚ሺ௫ሻכఘሺ௫ǡ௧ሻ
డ௫ ൌ Ͳǡ
ߩሺݔǡ Ͳሻ ൌ Ͳǡ
݃ሺͳሻ כ ߩሺͳǡ ݐሻ ൌ ׬ ߚሺݔሻ כ ߩሺݔǡ ݐሻ݀ݔ ൅ ߚ ቀܺ௣ሺݐሻቁ Ǥஶଵ
         (12) 
with ߩሺݔǡ ݐሻ being the density of metastases in the patient's body (i.e., the number of tumours containing x cells at time 
t), and ݃ሺݔሻ being the function defined in Section 4.2.1. Both parameters m and Į2 are specific to each patient and have a 
normal distribution, which are determined thanks to [20] and [29]. 
The value of interest for the decision-making is the Metastatic Index (MIn). It is defined by equation (13) in [20]. It 
represents the total number of metastatic tumors of size between n and ܺ௣ሺݐሻ in the patient's body at time T.  
ܯܫ௡ሺܶሻ ൌ ׬ ߩሺݔǡ ܶሻ݀ݔ௑೛ሺ்ሻ௡          (13) 
The resolution of the Iwata model is more complex than that of the primary tumor. Furthermore, there is general solution 
of this model with a function ݃ሺݔሻ with chemotherapy. Therefore, in order to keep calculation time reasonable within the 
simulation environment, the Iwata model is only used to describe the evolution of metastases without treatment using 
function ݃ሺݔሻ defined in equation (2). 
4.6. Metastases growth during chemotherapy:  
Granted there is no general solution to the Iwata model with chemotherapy, in order to determine the effects of 
chemotherapy on metastases, we first made three assumptions:  
Cancer cell dispersion in the body (i.e., ߚሺݔሻ) is neglected. Because cancer cell progressing through the patient's body is 
directly in contact with the drug, we assume it is automatically destroyed.  
All metastatic tumours evolve along the same decay law as the primary tumour under chemotherapy. In this study, we 
use equation (6): 
The number of tumours given byߩሺݔǡ ௖ܶሻ, as defined in (12) at the end of the free evolution of metastases, remains 
unchanged during the chemotherapy treatment. Only the tumour’s size is affected.  
Based on these hypothesis, the new distribution of metastases during chemotherapy ሺݐ ൐ ௖ܶሻ can be calculated based on 
ߩሺݔǡ ௖ܶሻ as defined at the end of the free evolution of metastases, using equation (14): 
ߩሺ ଵܺǡ ݐሻ ൌ ߩሺܺଶǡ ௖ܶሻݓ݅ݐ݄ ଵܺ ൌ ܺ௣௖ሺܺଶǡ ݐሻ     (14) 
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We define a new function ܺ௣௖ିଵ as. 
ܺ௣௖ିଵሺ ଵܺǡ ݐሻ ൌ ܺଶ ൌ ௑భ
௘׬ ൫ೌ೎షಶሺೞሻ൯
೟
೅೎ ೏ೞ
       (15) 
Therefore, MI during chemotherapy can be calculated using equation (15):
ܯܫ௡ሺݐሻ ൌ ׬ ߩ൫ܺ௣௖ିଵሺݔǡ ݐሻǡ ௖ܶ൯݀ݔ௑೛೎൫௑೛ሺ ೎்ሻǡ௧൯௡         (16) 
5. Model validation  
In order to validate the model, we carried out one experiment, using our simulation platform (based in the JADE 
Platform) with a 3,5GHz Intel Core i7 processor and 32 Go of RAM. This experiment aim at assessing the ability of 
the model to replicate the results of different clinical studies with specific treatment protocols. In this experiment, in 
order to compare the simulation results with actual data, we used the standard classification criteria of the World 
Health Organization [31], which are also used in the clinical studies used for validation. This classification 
distinguishes patients according to the cancer response (i.e., partial response (PR); complete response (CR); stable 
disease (SD); and progressive disease (PD)). Due to the limits of our model, which does not currently take into account 
patient mortality, it was not possible to consider other criteria such as the overall survival (OS), the disease free 
survival (DFS) and the progression free survival (PFS). 
In this experiment, we must first calibrate the model’s parameters. In order to do so, we use data from two clinical studies 
[32, 33], which allows us to validate our metastases growth model during chemotherapy treatment. Indeed, as it is the least 
documented and modeled part of the cancer evolution, we prioritize the validation of this part of the model. The data from 
these clinical studies includes the stage of the cancer, the method of patient selection and the protocol of treatment received 
by patients for Capecitabine chemotherapy. This study tested two administration protocols (i.e., a and b) on a sample of 35 
and 40 patients. Patients in the protocol a received two daily doses from day 1 to 14, followed by a period of rest (day 15 
until 21), and followed by a new treatment cycle starting on day 22. Patients in the protocol b received two daily doses 
continuously without rest periods. The model was calibrated for these two administrations protocols and for both sample 
sizes.  
5.1. Selection of the virtual population 
For each protocol/population we aim to replicate, we must first create several populations of virtual patients. To do 
so, it is not possible to simply create a virtual population with similar statistics as the real population. Indeed, the 
metastases distribution is correlated with the characteristics of the primary tumor because they share parameters. 
Therefore, we have to simulate all virtual patients starting at T0, when the first cancer cell appears. Subsequently, we 
determine two dates per patient, T1 and T2, respectively, when the tumor size falls within the range of interest, as 
defined by the studies, and when it comes out of this range. The date of diagnosis Td is selected randomly between 
T1 and T2. 
Once the diagnosis date is fixed, we determine the stage of the patient. From this large population of virtual patients, 
we select those whose characteristics are similar to the actual population to create our population test. Thus the total 
number of virtual patients is known in advance and it is necessary to initially simulate a large number of patients to 
have a sufficiently large test population. In order to select a virtual population similar to the actual populations selected 
in clinical trials ([32, 33]), in the experiment below we took patients with stage 4 and with ܯܫହכଵ଴ఴ greater than 1, 
which corresponds to metastasis larger than 10mm. 
There are two ways to generate populations: we can generate the populations randomly or we can generate 
populations based on the real data stored in the access document. In the following, all generated data must be stored 
in txt file, this file contains all the necessary information   (Age, diagnosis day, cancer type, tumor size, stage and 
treatment plan) to start the treatment phase. During the generation of populations (Agent patients), the physician agents 
are used in collaboration with the nurses agents to diagnose patients and to establish a treatment plan for each patient.  
5.2. Simulation results 
Two simulation tests were carried out for each set of parameters. In all tests, the virtual population samples were, 
like for calibration, similar in size to those of the two studies. In other words, protocol b of study 1 was tested with 
samples of 40 patients, protocol a of study 1 was tested with samples of 35 patients. During the simulation tests, to 
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reduce the possible variations, we tested an average of 10 samples of population for study 1, and an average of 3 for 
study 2. The model results of the simulation tests are fairly consistent with the results of the studies, and our model 
can adequately reproduce reality.  
Fig. 2 describes the average value of E of the simulation tests for each experiment. 
Protocol b study 1     Protocol a study 1 
Fig. 2. Comparative analysis
6. Conclusion and future work 
This paper introduced a conceptual model aiming at the development of a simulation environment capable of emulating 
the simultaneous care trajectories of several of cancer patients. More specifically, this paper introduces a cancer evolution 
model, which is the first developmental step of such a simulation environment. 
Before this model can be implemented and tested within the simulation environment, several other aspects of the 
conceptual model presented in Fig. 1 will have to be developed. Along the same line, the hospital resources and management 
processes will have to be modeled as well. But one of the first things to do before its integration into the simulation platform 
will be to validate the entire model with actual data from the hospital. 
Once completed, the configuration of the many agents of this simulation platform will be adjusted in order to emulate 
accurately reality. This paper shows that preliminary results indicate that it is possible to develop such a model, although 
development and analysis are required. 
The validation of the entire simulation environment with respect to actually data for a hospital will be part of an extensive 
aspect of the project. Once validated, this simulation will be used by the hospital in order to evaluate the benefits of specific 
organizational changes to both the hospital performance and the patients’ quality of life. 
Concerning the development of the simulation platform, the next step is be to calibrate and test this model with other 
chemotherapies and treatment protocols with specific patient data. However, there is still much work to do to improve this 
overall model. For instance, one general improvement concerns the modeling of the combined effects of radiation and 
chemotherapy administered simultaneously. Another important aspect concerns the modeling of the interactions between 
cancer treatments and the treatments of other health issues (i.e., co-morbidity).  
Concerning the modeling of new treatment, the second should also be adapted to include the impact of internal radiation 
therapy (i.e., brachytherapy) as it is more and more used in hospitals. Moreover, it would also be useful to take into account 
the interactions between the different treatments as surgery impacts metastasis’ angiogenesis, which makes metastasis grow 
faster [30]. In addition, long-term effects of treatment should be integrated as the tumor may take some time to regrow after 
radiation therapy. However, these effects are often random and causes for their presence or absence are unknown, making 
them difficult to model. Eventually, the model must also include mortality and its expected step for any medium term 
following work.  
Percentage (%) 
Response 
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